Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown(City Of Hope National Medical Center), Michael C. Jensen(Seattle Children's Hospital), Stephen J. Forman(City Of Hope National Medical Center), Massimo D’Apuzzo(City Of Hope National Medical Center), Michael E. Barish(City Of Hope National Medical Center), Jamie R. Wagner(City Of Hope National Medical Center), Renate Starr(City of Hope), Behnam Badie(City Of Hope National Medical Center), Jana Portnow(City of Hope), Julie A. Ressler(City Of Hope National Medical Center), Christine L. Wright(City Of Hope National Medical Center), Wen-Chung Chang(City Of Hope National Medical Center), Araceli Naranjo(CTI BioPharma (United Kingdom)), James R. Bading(City Of Hope National Medical Center), Julie R. Ostberg(CTI BioPharma (United Kingdom)), Yubo Zhai(City Of Hope National Medical Center), Lihong Weng(CTI BioPharma (United Kingdom))
Cited by 754
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k